Cryoport Stock Forecast, Price & News

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cryoport in the last twelve months. There are currently 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" Cryoport stock.
View analyst ratings for Cryoport or view top-rated stocks.

Wall Street analysts have given Cryoport a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Cryoport wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Cryoport is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Cryoport.

Cryoport, Inc. (NASDAQ:CYRX) posted its quarterly earnings results on Tuesday, May, 4th. The consumer goods maker reported ($0.13) EPS for the quarter, beating the consensus estimate of ($0.21) by $0.08. The consumer goods maker had revenue of $53.30 million for the quarter, compared to analyst estimates of $46.78 million. Cryoport had a positive trailing twelve-month return on equity of 3.17% and a negative net margin of 26.41%. The company's revenue was up 443.9% on a year-over-year basis. During the same quarter in the prior year, the business earned ($0.11) EPS.
View Cryoport's earnings history.

Cryoport's stock was trading at $16.62 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, CYRX shares have increased by 268.8% and is now trading at $61.30.
View which stocks have been most impacted by COVID-19.

7 brokers have issued 12 month price targets for Cryoport's stock. Their forecasts range from $44.00 to $84.00. On average, they expect Cryoport's share price to reach $72.57 in the next twelve months. This suggests a possible upside of 18.4% from the stock's current price.
View analysts' price targets for Cryoport or view top-rated stocks among Wall Street analysts.

Some companies that are related to Cryoport include Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), Jazz Pharmaceuticals (JAZZ), BridgeBio Pharma (BBIO), Arrowhead Pharmaceuticals (ARWR), Mirati Therapeutics (MRTX), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Evotec (EVTCY), Ultragenyx Pharmaceutical (RARE), Sarepta Therapeutics (SRPT), Biohaven Pharmaceutical (BHVN), Perrigo (PRGO), Ionis Pharmaceuticals (IONS) and I-Mab (IMAB).
View all of CYRX's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Cryoport investors own include Gilead Sciences (GILD), Advanced Micro Devices (AMD), Micron Technology (MU), NVIDIA (NVDA), Taiwan Semiconductor Manufacturing (TSM), Amarin (AMRN), QUALCOMM (QCOM), Enterprise Products Partners (EPD), Pfizer (PFE) and Square (SQ).

Cryoport trades on the NASDAQ under the ticker symbol "CYRX."

Cryoport's stock is owned by a variety of institutional and retail investors. Top institutional investors include Fred Alger Management LLC (13.15%), BlackRock Inc. (7.46%), Chevy Chase Trust Holdings Inc. (4.45%), Blackstone Group Inc. (4.35%), Granite Investment Partners LLC (2.47%) and Massachusetts Financial Services Co. MA (2.42%). Company insiders that own Cryoport stock include Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Jerrell Shelton, Mark W Sawicki, Richard J Berman and Robert Stefanovich.
View institutional ownership trends for Cryoport.

CYRX stock was sold by a variety of institutional investors in the last quarter, including Ikarian Capital LLC, Janus Henderson Group PLC, Royce & Associates LP, Taylor Wealth Management Partners, Clearbridge Investments LLC, Braun Stacey Associates Inc., Chevy Chase Trust Holdings Inc., and UBS Group AG. Company insiders that have sold Cryoport company stock in the last year include Daniel M Hancock, Edward J Zecchini, Freeze Parent LP Blackstone, Mark W Sawicki, and Richard J Berman.
View insider buying and selling activity for Cryoport or view top insider-selling stocks.

CYRX stock was bought by a variety of institutional investors in the last quarter, including Blackstone Group Inc., Granite Investment Partners LLC, BlackRock Inc., Alyeska Investment Group L.P., Northern Trust Corp, GW&K Investment Management LLC, Geode Capital Management LLC, and Renaissance Technologies LLC.
View insider buying and selling activity for Cryoport or or view top insider-buying stocks.

Shares of CYRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of CYRX stock can currently be purchased for approximately $61.30.

Cryoport has a market capitalization of $2.80 billion and generates $78.70 million in revenue each year. The consumer goods maker earns $-32,690,000.00 in net income (profit) each year or ($0.84) on an earnings per share basis.

Cryoport employs 650 workers across the globe.

The official website for Cryoport is www.cryoport.com.

Cryoport is headquartered at 112 Westwood Place Suite 350, Brentwood TN, 37027.

Cryoport's mailing address is 112 Westwood Place Suite 350, Brentwood TN, 37027. The consumer goods maker can be reached via phone at 949-470-2300 or via email at [email protected]